Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 3
2012 2
2013 3
2014 2
2015 6
2016 3
2017 4
2018 7
2019 8
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
Age-related mutations and chronic myelomonocytic leukemia.
Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, O'Hare T, Deininger MW. Mason CC, et al. Among authors: pomicter ad. Leukemia. 2016 Apr;30(4):906-13. doi: 10.1038/leu.2015.337. Epub 2015 Dec 9. Leukemia. 2016. PMID: 26648538 Free PMC article.
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW. Eide CA, et al. Among authors: pomicter ad. Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19. Cancer Cell. 2019. PMID: 31543464 Free PMC article.
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T. Zabriskie MS, et al. Among authors: pomicter ad. Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14. Cancer Cell. 2014. PMID: 25132497 Free PMC article.
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Yan D, Pomicter AD, O'Hare T, Deininger MW. Yan D, et al. Among authors: pomicter ad. Clin Cancer Res. 2019 Nov 15;25(22):6561-6563. doi: 10.1158/1078-0432.CCR-19-2270. Epub 2019 Sep 20. Clin Cancer Res. 2019. PMID: 31540978 Free PMC article.
Myelin, DIGs, and membrane rafts in the central nervous system.
Dupree JL, Pomicter AD. Dupree JL, et al. Among authors: pomicter ad. Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):118-29. doi: 10.1016/j.prostaglandins.2009.04.005. Epub 2009 Apr 18. Prostaglandins Other Lipid Mediat. 2010. PMID: 19379822 Review.
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T. Qiang W, et al. Among authors: pomicter ad. Leukemia. 2017 Dec;31(12):2844-2847. doi: 10.1038/leu.2017.264. Epub 2017 Aug 18. Leukemia. 2017. PMID: 28819281 Free PMC article. Clinical Trial. No abstract available.
Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW. Yan D, et al. Among authors: pomicter ad. Clin Cancer Res. 2019 Apr 1;25(7):2323-2335. doi: 10.1158/1078-0432.CCR-18-0959. Epub 2018 Dec 18. Clin Cancer Res. 2019. PMID: 30563936 Free PMC article.
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page